Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecfidera effect on fatigue and fatigability in relapsing-remitting multiple sclerosis
NL-OMON44334Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dimethyl fumarate in multiple sclerosis (MS), sponsored by University Medical Center Groningen. Primary endpoint: Association between fatigue and fatigability after 16 weeks of Tecfidera. Started Dec 2018; status: active, not recruiting.
02
Drugs
dimethyl fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON44334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44334.